Cargando…

Efficacy and Immunomodulating Properties of Eltrombopag in Aplastic Anemia following Autologous Stem Cell Transplant: Case Report and Review of the Literature

Thrombopoietin receptor agonists (TPO-RA) are currently indicated for the treatment of chronic immune thrombocytopenia and relapsed refractory aplastic anemia. However, the off-label use of these drugs is more and more frequent, including in the setting of aplasia secondary to chemotherapy and hemop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bortolotti, Marta, Pettine, Loredana, Zaninoni, Anna, Croci, Giorgio Alberto, Barcellini, Wilma, Fattizzo, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032708/ https://www.ncbi.nlm.nih.gov/pubmed/35455416 http://dx.doi.org/10.3390/ph15040419

Ejemplares similares

Cytokine polymorphisms in patients with autoimmune hemolytic anemia
por: Zaninoni, Anna, et al.
Publicado: (2023)

P1583: TRANSFUSIONS IN AUTOIMMUNE HEMOLYTIC ANEMIA: FREQUENCY AND CLINICAL SIGNIFICANCE OF ALLOIMMUNIZATION
por: Versino, Francesco, et al.
Publicado: (2023)

Pulmonary embolism in a patient with eltrombopag-treated aplastic anaemia and paroxysmal nocturnal haemoglobinuria clone during COVID-19 pneumonia
por: Alessandro, Bosi, et al.
Publicado: (2022)

Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives
por: Barcellini, Wilma, et al.
Publicado: (2019)

Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The “Seed and Soil” Crosstalk
por: Fattizzo, Bruno, et al.
Publicado: (2020)

P1568: NATURAL HISTORY OF CHRONIC ISOLATED NEUTROPENIA: A SINGLE CENTER OBSERVATIONAL STUDY
por: Sorrenti, Michele, et al.
Publicado: (2023)

New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy
por: Barcellini, Wilma, et al.
Publicado: (2020)

Eltrombopag for the treatment of aplastic anemia: current perspectives
por: Lum, Su Han, et al.
Publicado: (2016)

Aplastic Anemia Treated with Eltrombopag during Pregnancy
por: Suminaga, Yuri, et al.
Publicado: (2022)

Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study
por: Fattizzo, Bruno, et al.
Publicado: (2023)

Correction: Pulmonary embolism in a patient with eltrombopag-treated aplastic anaemia and paroxysmal nocturnal haemoglobinuria clone during COVID-19 pneumonia
por: Bosi, Alessandro, et al.
Publicado: (2022)

Small Paroxysmal Nocturnal Hemoglobinuria Clones in Autoimmune Hemolytic Anemia: Clinical Implications and Different Cytokine Patterns in Positive and Negative Patients
por: Fattizzo, Bruno, et al.
Publicado: (2020)

The Changing Landscape of Autoimmune Hemolytic Anemia
por: Barcellini, Wilma, et al.
Publicado: (2020)

Diagnosis and Management of Autoimmune Hemolytic Anemias
por: Barcellini, Wilma, et al.
Publicado: (2022)

Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
por: Konishi, Akiko, et al.
Publicado: (2019)

Current evidence and the emerging role of eltrombopag in severe aplastic anemia
por: Drexler, Beatrice, et al.
Publicado: (2021)

Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag
por: Zaimoku, Yoshitaka, et al.
Publicado: (2021)

Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia
por: Zhao, Yufei, et al.
Publicado: (2023)

PB1990: GLYCOLYTIC ACTIVITY AND EFFECT OF EX-VIVO TREATMENT WITH THE PYRUVATE KINASE (PK) ACTIVATOR AG-946 IN RED BLOOD CELLS FROM LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS: A PROOF-OF-CONCEPT STUDY
por: Fattizzo, Bruno, et al.
Publicado: (2023)

Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature
por: Galli, Nicole, et al.
Publicado: (2023)

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia
por: Lengline, Etienne, et al.
Publicado: (2018)

Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia
por: Goronkova, Olga, et al.
Publicado: (2022)

Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers
por: Wan, Ziqi, et al.
Publicado: (2023)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
por: Chang, Hong, et al.
Publicado: (2023)

Off-Label Use of Thrombopoietin Receptor Agonists: Case Series and Review of the Literature
por: Capecchi, Marco, et al.
Publicado: (2021)

The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket?
por: Berentsen, Sigbjørn, et al.
Publicado: (2023)

PB1935: MANAGEMENT OF NON-SEVERE APLASTIC ANEMIA: LABORATORY WORKUP AND TREATMENT PATTERNS.
por: Cassanello, G., et al.
Publicado: (2022)

Bortezomib in autoimmune hemolytic anemia and beyond
por: Pasquale, Raffaella, et al.
Publicado: (2021)

Infectious Complications in Autoimmune Hemolytic Anemia
por: Giannotta, Juri Alessandro, et al.
Publicado: (2021)

Autoimmune Hemolytic Anemia as a Complication of Congenital Anemias. A Case Series and Review of the Literature
por: Motta, Irene, et al.
Publicado: (2021)

The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
por: Işık, Ayşe, et al.
Publicado: (2013)

Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States
por: Tremblay, Gabriel, et al.
Publicado: (2019)

Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia
por: Guan, Yihong, et al.
Publicado: (2022)

The efficacy and the safety of eltrombopag in pediatric patients with severe aplastic anemia: a systematic review
por: Marrapodi, Maria Maddalena, et al.
Publicado: (2023)

Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience
por: Fattizzo, Bruno, et al.
Publicado: (2022)

P1482: RECOMBINANT ERYTHROPOIETIN IN AUTOIMMUNE HEMOLYTIC ANEMIA WITH INADEQUATE RETICULOCYTOSIS: A SINGLE CENTER PROSPECTIVE STUDY
por: Luca Pedone, Giacinto, et al.
Publicado: (2023)

Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature
por: Fattizzo, Bruno, et al.
Publicado: (2021)

Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia
por: Fattizzo, Bruno, et al.
Publicado: (2021)

Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience
por: Abbasi, Abdul Muqtadir, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b2l0etb11krkpae0qmqro2jj85